Patient, kind, and always approachable.
Nat Milton is Professor in Biomedical Science at the University of Chichester, joining in 2024 to help establish the Community Diagnostics Centre and develop new Biomedical Science courses within the Faculty of Health. He earned a BSc in Zoology from the University of Edinburgh and a PhD in Neuroendocrinology from the University of London, where he served as the first Marjorie A. Robinson Fellow funded by the Society for Endocrinology. His career includes roles in Clinical Biochemistry at NHS departments in Newcastle and London, academic positions at several universities in London and Leeds, and founding NeuroDelta Ltd in 2003 to develop novel compounds via in silico techniques. Professor Milton has taught undergraduate and postgraduate courses in Physiology, Pharmacology, Clinical Biochemistry, Neuroscience, and Entrepreneurship. He holds fellowships from the Royal Society of Biology, Institute of Biomedical Science, Institute of Enterprise and Entrepreneurs, and Higher Education Academy.
Professor Milton's research centers on Alzheimer’s drug discovery and diagnostics, exploring amyloid peptides in Alzheimer’s disease, diabetes, Creutzfeldt-Jakob disease, and oxidative stress responses. Key discoveries include neuroprotective effects of endogenous cannabinoids like anandamide against amyloid-β neurotoxicity, KiSS-1 derivatives such as kissorphin as anti-opioid peptides binding amyloid proteins, and bioinformatics analyses of protein interactions like amyloid-β with catalase for therapeutic applications. Notable publications encompass 'SARS-CoV-2 amyloid, is COVID-19-exacerbated dementia an amyloid disorder in the making?' (Frontiers in Dementia, 2023), 'Kissorphin peptides for use in the treatment of Alzheimer’s disease, Creutzfeldt-Jakob disease or diabetes mellitus' (UK Patent GB2493313B, 2017), and the book chapter 'Polymorphism of Amyloid Fibrils and their Complexes with Catalase' (Bio-nanoimaging, 2014). He presented his inaugural lecture, 'Amyloid-β, the Poison in Your Human Machine,' at the University of Chichester.